Molecular Analysis and Treatment Options of Thymic Malignancies

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorShanghai Chest Hospital

About this trial

Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies.

In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Histologically proven diagnosis of thymic malignancies

18 years of age or older

Ability to understand and the willingness to sign a written informed consent document

Disqualifiers

None

Trial population

Participants with thymic malignancies are with the standard treatment and/or are enrolled in the clinical trials.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • Chemotherapy

    Drug

    different treatments based on the molecular analysis

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Objective response rate (ORR)

Collect detailed clinical information on patients with thymic malignancies via the electronic medical records

Time frame
20 years
2

Disease control rate (DCR)

Collect detailed clinical information on patients with thymic malignancies via the electronic medical records

Time frame
20 years
3

Progression-free survival (PFS)

Collect detailed clinical information on patients with thymic malignancies via the electronic medical records

Time frame
20 years

Secondary outcomes

1

Overall survival (OS)

Collect detailed clinical information on patients with thymic malignancies via the electronic medical records

Time frame
20 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.